These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 15272064)

  • 1. Anaerobic incubation conditions enhance pyrazinamide activity against Mycobacterium tuberculosis.
    Wade MM; Zhang Y
    J Med Microbiol; 2004 Aug; 53(Pt 8):769-773. PubMed ID: 15272064
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhancement of the antituberculosis activity of weak acids by inhibitors of energy metabolism but not by anaerobiosis suggests that weak acids act differently from the front-line tuberculosis drug pyrazinamide.
    Gu P; Constantino L; Zhang Y
    J Med Microbiol; 2008 Sep; 57(Pt 9):1129-1134. PubMed ID: 18719183
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conditions that may affect the results of susceptibility testing of Mycobacterium tuberculosis to pyrazinamide.
    Zhang Y; Permar S; Sun Z
    J Med Microbiol; 2002 Jan; 51(1):42-49. PubMed ID: 11800471
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nutrient-starved incubation conditions enhance pyrazinamide activity against Mycobacterium tuberculosis.
    Huang Q; Chen ZF; Li YY; Zhang Y; Ren Y; Fu Z; Xu SQ
    Chemotherapy; 2007; 53(5):338-43. PubMed ID: 17785970
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of acid pH and deficient efflux of pyrazinoic acid in unique susceptibility of Mycobacterium tuberculosis to pyrazinamide.
    Zhang Y; Scorpio A; Nikaido H; Sun Z
    J Bacteriol; 1999 Apr; 181(7):2044-9. PubMed ID: 10094680
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Nutrient starved incubation conditions enhance pyrazinamide activity against Mycobacterium tuberculosis].
    Chen ZF; Huang Q; Li YY; Zhang Y; Ren Y; Li KS; Fu ZJ; Xu SQ
    Zhonghua Jie He He Hu Xi Za Zhi; 2007 May; 30(5):359-62. PubMed ID: 17651643
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pyrazinamide inhibits the eukaryotic-like fatty acid synthetase I (FASI) of Mycobacterium tuberculosis.
    Zimhony O; Cox JS; Welch JT; Vilchèze C; Jacobs WR
    Nat Med; 2000 Sep; 6(9):1043-7. PubMed ID: 10973326
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanisms of pyrazinamide resistance in mycobacteria: importance of lack of uptake in addition to lack of pyrazinamidase activity.
    Raynaud C; Lanéelle MA; Senaratne RH; Draper P; Lanéelle G; Daffé M
    Microbiology (Reading); 1999 Jun; 145 ( Pt 6)():1359-1367. PubMed ID: 10411262
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The paradox of pyrazinamide: an update on the molecular mechanisms of pyrazinamide resistance in Mycobacteria.
    Singh P; Mishra AK; Malonia SK; Chauhan DS; Sharma VD; Venkatesan K; Katoch VM
    J Commun Dis; 2006 Mar; 38(3):288-98. PubMed ID: 17373362
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activity of 5-chloro-pyrazinamide in mice infected with Mycobacterium tuberculosis or Mycobacterium bovis.
    Ahmad Z; Tyagi S; Minkowsk A; Almeida D; Nuermberger EL; Peck KM; Welch JT; Baughn AS; Jacobs WR; Grosset JH
    Indian J Med Res; 2012 Nov; 136(5):808-14. PubMed ID: 23287128
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activity of n-propyl pyrazinoate against pyrazinamide-resistant Mycobacterium tuberculosis: investigations into mechanism of action of and mechanism of resistance to pyrazinamide.
    Speirs RJ; Welch JT; Cynamon MH
    Antimicrob Agents Chemother; 1995 Jun; 39(6):1269-71. PubMed ID: 7574514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pantothenate and pantetheine antagonize the antitubercular activity of pyrazinamide.
    Dillon NA; Peterson ND; Rosen BC; Baughn AD
    Antimicrob Agents Chemother; 2014 Dec; 58(12):7258-63. PubMed ID: 25246400
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A new approach for pyrazinamide susceptibility testing in Mycobacterium tuberculosis.
    Zimic M; Loli S; Gilman RH; Gutierrez A; Fuentes P; Cotrina M; Kirwan D; Sheen P
    Microb Drug Resist; 2012 Aug; 18(4):372-5. PubMed ID: 22372927
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pyrazinoic Acid Inhibits a Bifunctional Enzyme in Mycobacterium tuberculosis.
    Njire M; Wang N; Wang B; Tan Y; Cai X; Liu Y; Mugweru J; Guo J; Hameed HMA; Tan S; Liu J; Yew WW; Nuermberger E; Lamichhane G; Liu J; Zhang T
    Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28438933
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-Chain Fatty Acyl Coenzyme A Ligase FadD2 Mediates Intrinsic Pyrazinamide Resistance in Mycobacterium tuberculosis.
    Rosen BC; Dillon NA; Peterson ND; Minato Y; Baughn AD
    Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27855077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of growth rate on pyrazinamide activity in Mycobacterium tuberculosis - insights for early bactericidal activity?
    Pullan ST; Allnutt JC; Devine R; Hatch KA; Jeeves RE; Hendon-Dunn CL; Marsh PD; Bacon J
    BMC Infect Dis; 2016 May; 16():205. PubMed ID: 27184366
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sterilising action of pyrazinamide in models of dormant and rifampicin-tolerant Mycobacterium tuberculosis.
    Hu Y; Coates AR; Mitchison DA
    Int J Tuberc Lung Dis; 2006 Mar; 10(3):317-22. PubMed ID: 16562713
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mode of action of pyrazinamide: disruption of Mycobacterium tuberculosis membrane transport and energetics by pyrazinoic acid.
    Zhang Y; Wade MM; Scorpio A; Zhang H; Sun Z
    J Antimicrob Chemother; 2003 Nov; 52(5):790-5. PubMed ID: 14563891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rapid colorimetric pyrazinamide susceptibility testing of Mycobacterium tuberculosis.
    Li H; Zhou LP; Luo J; Yu JP; Yang H; Wei HP
    Int J Tuberc Lung Dis; 2016 Apr; 20(4):462-7. PubMed ID: 26970154
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In Vivo-Selected Pyrazinoic Acid-Resistant Mycobacterium tuberculosis Strains Harbor Missense Mutations in the Aspartate Decarboxylase PanD and the Unfoldase ClpC1.
    Gopal P; Tasneen R; Yee M; Lanoix JP; Sarathy J; Rasic G; Li L; Dartois V; Nuermberger E; Dick T
    ACS Infect Dis; 2017 Jul; 3(7):492-501. PubMed ID: 28271875
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.